New Reporting Exposes Big Pharma’s Lies On Inflation, Medicare Savings, And Generic Competition

WASHINGTON, D.C. —As Congress is poised to pass the largest health care bill since the Affordable Care Act, Big Pharma is using every scare tactic possible to try to stop the Inflation Reduction Act from passing. This week, independent experts debunked the industry’s lies about the drug price provisions’ impact on innovation, Medicare savings, and generic competition.

Here’s a round-up:  

  1. Inflation: Big Pharma falsely claims “prescription drug prices are not fueling inflation.”

2. Medicare Savings: Big Pharma falsely claims the bill will “strip $300 billion from Medicare.”

3. Generic Competition: The drug industry falsely claims that the bill will make less-expensive generic drugs less likely to come to market.

For more on debunking pharma, check out these resources